Bojan Lalovic

Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study

Brian G. Feagan, William J. Sandborn, Geert D’Haens et al. · The Lancet · 2017 · 446 citations · Full text

Life Sciences, Immunology, Pharmacology +16

Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: Role of circulating active metabolites

Bojan Lalovic, Evan D. Kharasch, Danny D. Shen · Clinical Pharmacology & Therapeutics · 2006 · 416 citations

Medicine, Pharmacokinetics, Pharmacology +10

QUANTITATIVE CONTRIBUTION OF CYP2D6 AND CYP3A TO OXYCODONE METABOLISM IN HUMAN LIVER AND INTESTINAL MICROSOMES

Bojan Lalovic, Brian Phillips, Linda L. Risler et al. · Drug Metabolism and Disposition · 2004 · 254 citations

Medicine, Pharmacokinetics, Pharmacology +15

Anti–IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial

James G. Krueger, Laura K. Ferris, Alan Menter et al. · Journal of Allergy and Clinical Immunology · 2015 · 250 citations

Medicine, Immunology, Pharmacology +15

Psoriatic skin molecular and histopathologic profiles after treatment with risankizumab versus ustekinumab

Sudha Visvanathan, Patrick Baum, Richard Vinisko et al. · Journal of Allergy and Clinical Immunology · 2018 · 68 citations · Full text

Medicine, Dermatology, Immunology +17